- Home
- LILAK vs PSNL Comparison
LILAK vs PSNL Comparison
Compare LILAK & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LILAK | PSNL |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Medical Specialities |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LILAK | PSNL |
|---|---|---|
| Price | $9.81 | $15.72 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 5 |
| Target Price | $8.20 | ★ $15.17 |
| AVG Volume (30 Days) | 1.7M | ★ 2.1M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.55 | ★ 33.58 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,442,200,000.00 | $69,648,000.00 |
| Revenue This Year | $0.60 | $27.28 |
| Revenue Next Year | $3.23 | $24.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.75 | $4.96 |
| 52 Week High | $10.42 | $18.89 |
Technical Indicators
Market Signals| Indicator | LILAK | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 67.41 | 44.34 |
| Support Level | $7.44 | $15.51 |
| Resistance Level | N/A | $16.49 |
| Average True Range (ATR) | 0.48 | 0.24 |
| MACD | 0.18 | 0.01 |
| Stochastic Oscillator | 76.79 | 31.97 |
Price Performance
Historical ComparisonAbout LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.